AbbVie Reports Improved Facial Satisfaction Among GLP-1 Weight-Loss Medication Users
AbbVie (ABBV) announced findings from two clinical studies conducted by its Allergan Aesthetics division regarding patients using GLP-1 weight-loss medications. The data indicates that users of these drugs reported improved satisfaction with their facial appearance following specific cosmetic treatments. The results, presented at the American Society for Dermatologic Surgery's annual meeting, highlight a growing intersection between the popularity of weight-loss drugs and the demand for aesthetic medical procedures. This trend suggests potential market opportunities for AbbVie's aesthetics portfolio as patients seek to address facial volume loss often associated with rapid weight reduction.
Tickers: $ABBV
Topics: clinical studies cosmetic treatments GLP-1 medications weight loss side effects